Mobidiag signs new international agreements for distribution of its Amplidiag® and Novodiag® diagnostic solutions Agreements signed in Poland, Ukraine, Romania and Israel, with more in discussions.

ESPOO, Finland, October 29th, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has signed new exclusive agreements with international partners for the distribution of its Amplidiag^® and Novodiag^® products in Europe and the Middle East.

Mobidiag has signed exclusive agreements for the distribution of Amplidiag^® and Novodiag^® with ALAB Ltd. for Poland and Ukraine, BIOgenetiX for Romania and Theranostica Ltd. for Israel.

Tuomas Tenkanen, CEO of Mobidiag, said “We are extremely pleased to have further expanded our commercial footprint into additional international territories. Our highly versatile and complementary Amplidiag^® and Novodiag^® diagnostic solutions continue to gain traction internationally. We are in ongoing discussions with several distribution partners in a range of international markets as customers look for fast, accurate and affordable diagnostic solutions to a wide range of infectious diseases.”

Gilda Cristea, Imports Manager of BIOgenetiX, comments “It is a great opportunity for BIOgenetiX to collaborate with Mobidiag in Romania. The control of infections and the identification of antibiotic resistant pathogens are critical in all clinical environments. Mobidiag offers a diverse range of products that are easy to use, have great diagnostic precision and are affordable. These products are very important for the general management of patients and hospitals and we see them offering a great opportunity for the future.”

Amnon Hezkaya CEO of Theranostica, continues "We are really excited to start this partnership between Theranostica and Mobidiag. Mobidiag with its Novodiag^® solution has the potential to be transformational for Israeli clinical laboratory customers as an affordable, fast sample to result system, which can test multiple targets at once.”